Furthermore, our results support the idea that in addition to the well-known oncogenic function of mutant calreticulin in patients with ET and PMF by activating JAK/STAT signaling through its binding to the thrombopoietin receptor, there would also be a loss of function that may lead to major alterations [26]. This evidence concerns the gene CALR and essential thrombocythemia.